

# Michele M Gorczyca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4740079/publications.pdf>

Version: 2024-02-01

7  
papers

432  
citations

1478505

6  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

669  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , 2018, 19, 1641-1653.	10.7	193
2	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 6450-6458.	1.4	121
3	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1084-1093.	1.3	48
4	Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 449-452.	2.2	32
5	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2037-2046.	1.3	20
6	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3K $\beta$ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5248-5257.	7.0	15
7	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 348-356.	1.3	3